Skip to main content

Table 1 Patient baseline and disease characteristics

From: An open-label expanded access program of afatinib in EGFR tyrosine kinase inhibitor-naïve patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR mutations

Characteristic Treatment Set
N = 88
Age
 Median (range), years 61 (37–87)
  <  65 53 (60)
  ≥ 65 35 (40)
  ≥ 75 5 (6)
Sex
 Female 46 (52)
 Male 42 (48)
Smoking status
 Never 55 (63)
 Ex-smoker 27 (31)
 Current smoker 6 (7)
ECOG PS score
 0 15 (17)
 1 71 (81)
 2 2 (2)
Tumor histology
 Predominantly adenocarcinoma 87 (99)
 Predominantly squamous 1 (1)
Clinical stage at initial diagnosis
 IA 7 (8)
 IB 4 (5)
 IIA 1 (1)
 IIB 1 (1)
 IIIA 2 (2)
 IIIB 3 (3)
 IV 70 (80)
Metastases
 Any 86 (98)
 Brain 27 (31)
EGFR mutation categories
 Del19 51 (58)
 L858R 27 (31)
 Exon 20 insertions 3 (3)
 L861Q 6 (7)
 G719X 4 (5)
 T790M 2 (2)
 S768I 0
 Other 2 (2)
EGFR mutation
 Common 72 (82)
 Uncommon 16 (18)
Any previous systemic chemotherapies 30 (34)
  1. ECOG PS Eastern Cooperative Oncology Group performance status, EGFR epidermal growth factor receptor
  2. Data are n (%) unless otherwise stated